Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 23, 2026.

Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

Eduardo Ekman Schenberg

Frontiers in Pharmacology · 2018

doi:10.3389/fphar.2018.00733

Abstract

Mental disorders are rising while development of novel psychiatric medications is declining. This stall in innovation has also been linked with intense debates on the current diagnostics and explanations for mental disorders, together constituting a paradigmatic crisis. A radical innovation is psychedelic-assisted psychotherapy (PAP): professionally supervised use of ketamine, MDMA, psilocybin, LSD and ibogaine as part of elaborated psychotherapy programs. Clinical results so far have shown safety and efficacy, even for "treatment resistant" conditions, and thus deserve increasing attention from medical, psychological and psychiatric professionals. But more than novel treatments, the PAP model also has important consequences for the diagnostics and explanation axis of the psychiatric crisis, challenging the discrete nosological entities and advancing novel explanations for mental disorders and their treatment, in a model considerate of social and cultural factors, including adversities, trauma, and the therapeutic potential of some non-ordinary states of consciousness.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 23, 2026. Paragraph numbers are ours, so an answer can point at one.

The current psychiatric crisis

Mental disorders increasingly contribute to the global burden of disease, with huge socio-economic costs (Catalá-López et al.,; Whiteford et al., ). However, research and development in psychopharmacology—psychiatry's primary mode of intervention—came to a halt in 2010 (Miller,; Hyman, ). Approval of new molecular entities for psychiatric conditions by the US Food and Drug Administration (FDA) fell from 13 in 1996 to one in 2016, with 49 approved between 1996 and 2006 and 22 from 2007 to 20161 In pharmacology conferences in the period, just about 5% of presentations were dedicated to human studies involving drugs with novel mechanisms of action (van Gerven and Cohen, ). These occurrences are part of a complex picture clearly dissected as a triple crisis in psychiatry: of therapeutics, diagnostics and explanation (Rose, ).

Problems surrounding psychiatric diagnosis also surfaced in 2010, when the UK Medical Research Council published a strategy for mental health and wellbeing (Sahakian et al., ) and the US National Institute for Mental Health (NIMH) launched its Research Domain Criterion (RDoC). It proposed five domains based on specific neural systems that can be impaired in mental illness, a radical departure from the hundreds of discrete conceptual disorders of the much older Diagnostic and Statistical Manual (DSM) (Casey et al.,; Insel,; Kraemer, ). Thus, the RDoC advanced a multidimensional approach to diagnosing mental disorders in a continuous spectra (Adam, ). At around the same time, a network psychopathology perspective was conceptualized and empirically assessed with statistical models for psychometrics based on thousands of patient reports' and hundreds of symptoms (Fried et al., ).

The treatment and diagnostic axes of the crisis are connected by the explanatory domain: despite huge investment in neuroscience as the ultimate source for understanding mental illness, both classification and diagnosis (Stephan et al., ) as well as knowledge about pathogenesis and etiology still faces many challenges (Stephan et al., ). The explanatory debate about mental disorders is summarized by the contrasting declarations that “mental disorders are brain disorders” (Deacon,; Insel and Cuthbert, ) or that psychiatry runs the risk of “losing the psyche” (Parnas, ).

Clinical developments with psychedelics

Synthetic substances like Lysergic Acid Diethylamide (LSD), 3,4-MethylenodioxyMetamphetamine (MDMA), 2-(2-Chlorophenyl)-2-(methylamino) cyclohexanone (ketamine) and naturally occurring alkaloids including 4-phosphoriloxy-N,N-dimethyltryptamine (psilocybin, present in hundreds of Psilocybe mushroom species) and 12-Methoxyibogamine (ibogaine, from Tabernanthe iboga) have been used in a series of studies (Passie et al.,; Brown,; Tylš et al.,; Mithoefer et al.,; Nichols,; for reviews see Winkelman,; Dos Santos et al.,; Johnson and Griffiths,; Nichols et al., ) as well as Phase 2 clinical trials (Table 1). These substances are orally active but have different mechanisms of action. LSD and psilocybin effects' critically depend on 5-HT2A agonism, MDMA inhibits monoamine transporters, especially for serotonin, while ketamine is an NMDA antagonist and ibogaine non-specifically binds to many receptors.

The most studied is ketamine, which in higher doses is an anesthetic in use for decades. In lower dosages it temporarily modify consciousness including changes in mood and cognition (Mion, ). It is the experimental intervention in almost 70 Phase 2 trials for psychiatric disorders and two Phase 3 trials for depression. Protocols involve single or repeated administrations in different doses, routes of delivery and research designs. Most are for depressive disorders, but is also studied for Obsessive-Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), suicide, alcohol, and cocaine use disorders (Table 1). Nine meta-analysis from depression trials (Fond et al.,; Coyle and Laws,; Lee et al.,; McGirr et al.,; Parsaik et al.,; Romeo et al.,; Wan et al.,; Kishimoto et al.,; Xu et al., ) shows low frequency of serious adverse events in the short term (but see Short et al., for long-term reporting bias), with short-term positive outcomes for a significant proportion of patients.

MDMA is investigated in 17 Phase 2 trials (Table 1) and was designated a breakthrough therapy for PTSD by the FDA, a status that can expedite approval (Kupferschmidt, ). Also studied for social anxiety in autistic adults, existential anxiety and alcohol use disorder (Table 1), MDMA is commonly confused with the street drug “ecstasy” (also known as “molly”). However, these illegal products frequently do not contain MDMA, only adulterants (Vogels et al.,; Wood et al.,; Togni et al.,; Saleemi et al.,; Vrolijk et al., ). This loose terminology creates unfortunate confusion about MDMA's safety (Amoroso, ). In research with healthy volunteers, occurrences of hypertension, tachycardia and hyperthermia are below 1/3 of cases, not leading to serious adverse events (Vizeli and Liechti, ). In clinical populations, serious adverse events were very rare, with only one brief and self-limiting case of increased ventricular extrasystoles in more than 1,260 sessions (MAPS, ). Therapeutic results obtained with severe, treatment-resistant PTSD patients in Phase 2 studies were considered “spectacular” (Frood, ), with approximately 70% or more of participants no longer qualifying for the diagnosis after 12 months, while the remainder third had less intense symptoms. Furthermore, the improvements lasted up to 4 years, mostly without additional treatments and without inducing drug abuse or dependence (Mithoefer et al.,; Yazar-Klosinski and Mithoefer, ). An independent preliminary meta-analysis found MDMA-assisted psychotherapy was superior to prolonged exposure when evaluated by clinician-observed outcomes, by patient self-report outcomes and also by drop-outs (Amoroso and Workman, ).

Psilocybin is the third most studied psychedelic substance for clinical applications. It has a very high safety ratio (Gable,; Tylš et al., ) and very low risk profile even in unsupervised settings (Nutt et al.,; van Amsterdam et al.,;)2 It's orally administered in eight trials for major depression, cigarettes, alcohol, and cocaine use disorders and existential anxiety in life-threatening diseases, mostly cancer. Despite moderately increasing blood pressure (Griffiths et al., ) and inducing transient headaches (Johnson et al., ), it has been safely administered to more than a 100 volunteers in neuroscientific research (Studerus et al., ) and another 100 in clinical studies with notable results (Table 1).

LSD, the most potent psychedelic currently administered in clinical trials, has very slow dissociation kinetics at the human 5-HT2A receptor and thus long lasting effects (Wacker et al., ). It has a very high safety ratio (Gable,; Passie et al., ) and is not associated with major health impairments after unsupervised use (Krebs and Johansen,; Hendricks et al.,,; Johansen and Krebs, ). It is the active substance in just two recent Phase 2 trials for existential anxiety in the terminally ill (Table 1). This paucity is perhaps due to stigma surrounding large-scale recreational use since the 1960's, with considerable political implications (Dyck,; Nutt et al.,; Smith et al., ). However, before political turmoil, more than a 1,000 studies including 40,000 patients were done (Grinspoon, ), mostly showing positive potentials (Abraham et al., ). LSD was thus the prototypical substance in the development of radically new forms of psychotherapy, including psychedelic-assisted psychotherapy (Pahnke et al.,; Grof,, ) and another approach based on repeated low doses (10 to 50 μg) to potentiate psychoanalysis, known as psycholytic psychoherapy (Majić et al., ). Despite the paucity of recent trials, a recent meta-analysis with rigorous research from 60 years ago confirmed LSD also has important potential for alcohol use disorders (Krebs and Johansen, ).

Finally, ibogaine is the less advanced psychedelic in the development pipeline, with no interventional clinical trials executed or registered since the National Institute on Drug Abuse (NIDA) cancelled efforts to develop this compound to treat opioid addiction in the 1990's (Alper, ). And indeed there are important safety concerns, given ibogaine can prolong QT interval (Koenig and Hilber, ), potentially evolving to fatal cardiac arrhythmias (Koenig et al., ). This critically differentiates ibogaine's safety profile from other psychedelics. However, given the seriousness of drug addiction and the difficulty to treat these patients, observational and retrospective studies for opioid (Brown and Alper,; Noller et al., ) and psychostimulant addiction (Schenberg et al.,,, ) reporting considerable success suggests Phase 2 trials focusing on cardiac safety should be performed. Given ibogaine is unscheduled in many countries and currently used as an alternative treatment with an unfortunate series of fatalities (Alper et al., ), financial support is needed.

Psychedelic-assisted psychotherapy (PAP)

Safeguarded important differences regarding safety and mechanisms of action, the grouping of these substances in a prototypical PAP model has important practical and theoretical implications. The main feature is the therapeutic use of a potent psychoactive substance (currently most are scheduled compounds) in very few sessions. These are generally accompanied by drug-free sessions before and/or after drug sessions, usually called preparatory and integrative psychotherapy, respectively. With ketamine positive results were obtained with one to 12 administrations, with MDMA just three and with psilocybin and LSD only two, while ibogaine may be effective after a single administration. During drug effects, patients are continuously monitored and supported by trained mental health professionals following available guidelines (Johnson et al., )3. Generally patients listen to instrumental evocative music (Pahnke et al.,; Bonny and Pahnke,; Kaelen et al.,; Barrett et al.,; Richards, ) and are encouraged to stay introspective (with eyeshades) and open to feelings, attentive to thoughts and memories, being free to engage in psychotherapy at any time (Grof, ). Frequency and type of psychotherapeutic interventions varied from a minimum in ketamine studies, sometimes including only music during drug effects, to a more intensive protocol with MDMA including 12 non-drug sessions, which follow a detailed manual based on non-directive transpersonal psychology3 (recently, MDMA has also been tested with cognitive behavioral conjoint therapy). Between these two ends of the spectrum are psilocybin, LSD and ibogaine studies, which used a variety of interventions. Psilocybin studies used psychological support comprised of non-directive preparation, support and integration in few non-drug sessions. LSD included three post-drug integrative sessions. Ibogaine, used in different clinics for drug dependence, included a series of more or less standardized psychotherapies for addiction, pre- and post-drug, like 12-steps, individual and group counseling, among others. Increasing focus on types and frequency of psychotherapeutic interventions can arguably help improve outcomes, as exemplified by older ketamine studies with existentially oriented psychotherapy for drug addiction (e.g., Krupitsky and Grinenko,; Krupitsky et al., ) and as recently tested with cognitive behavioral therapy for relapse prevention after ketamine for depression (Wilkinson et al., ). As results from most trials reliably show, PAP can be more effective and faster than current treatments, even for patients considered “treatment resistant.” And these outcomes were not only statistically significant but had large effect sizes, which is encouraging for Phase 3 trials.

Beyond potential novel treatments, PAP has important practical and theoretical consequences for the three axes of the crisis. The combination of psychotherapy with psychedelics can be conceptualized as the induction of an experience with positive long-term mental health consequences, rather than daily neurochemical corrections in brain dysfunctions (Figure 1). Thus, a comprehensive understanding of PAP suggests a conceptual expansion of “drug efficacy” to “experience efficacy4” Instead of conceiving the drug as correcting functional imbalances in the brain through a specific receptor, PAP is a treatment modality in which specific pharmacological actions temporally induce modifications in brain functioning and conscious experience. When appropriately mediated, these can be deeply meaningful experiences that elicit the emotional, cognitive and behavioral changes reported. Attempts to develop ketamine and ibogaine analogs devoid of the subjective “psychedelic” effects, e.g., lanicemine and 18-MC, will further illuminate this question. However, available therapeutic results for depression with ketamine analogs with less dissociative effects were only modest (Iadarola et al., ), while ketamine administration without preparatory psychotherapy and music support recently resulted in an interrupted trial (Gálvez et al., ). Furthermore, positive correlations between subjective features like ketamine's dissociative effects (Luckenbaugh et al., ) or psilocybin peak-experience with positive treatment outcomes in depression (Roseman et al., ) corroborates the notion that the meanings of the psychedelic experience plays an important role in therapeutic outcomes (Grof,; Hartogsohn, ). It is thus very hard to strictly reduce PAP to neuropharmacology. In this sense, PAP can benefit from potentially rich interactions with other fields like psychodynamic psychotherapy (Plakun,, ). Furthermore, PAP can help solve many pressing safety concerns in current psychopharmacological treatments by bridging a current gap in knowledge between research and clinical practice. This gap is created because psychiatric clinical trials rarely last longer than 6 months (Downing et al., ), while the products approved based on these trials are later prescribed for chronic daily use for years, sometimes decades. Many current adverse consequences from the use of psychiatric prescription medications arise from this gap, including decreasing drug adherence over time (Chapman and Horne,; Medic et al., ), toxicity from increasing polypharmacy (Mojtabai and Olfson,; Kukreja et al., ), addiction to prescribed medications causing severe withdrawal symptoms (Wright et al.,; McHugh et al.,; Novak et al., ), and a plethora of side effects arising after prolonged daily drug use, e.g., weight changes, stomach pains, constipation, mood swings, confusion, abnormal thoughts, delusions, memory loss, restlessness, akathisia, tardive dyskinesia, sexual dysfunction, anxiety, dizziness, sleep problems, and even suicidal ideas5 By administering medications only under supervision, PAP can reduce or even eliminate drug adherence problems and polypharmacy. By administering psychoactive drugs just a few times, PAP can prevent addiction and the development of side effects after chronic use of medications. And by exclusively licensing psychedelics for especially licensed therapists and physicians, rather than prescription and dispensation to patients, PAP can reduce risks of diversion and abuse. Considered together, these PAP features can arguably help reduce psychiatry's alarmingly high-rate of post-market safety events, reported at more than 60% after 10 years (Downing et al., ).

Besides critical consequences for the therapeutic axis, PAP is also relevant for diagnostic concerns. The fact that ketamine and psilocybin, substances with radically different pharmacological mechanisms of action, can induce positive outcomes in a single disorder, like depression; or that a single substance like psilocybin can be used to treat different disorders, like depression or drug dependence, challenges nosologies which discriminate disorders in mutually-exclusive categories. Thus, PAP supports a multidimensional spectra (Figure 1). However, proposals such as the RDoC were criticized by its biomedical reductionism (Frances,; Parnas,; Wakefield, ), while psychedelic research recognize the concept of set and setting (Eisner,; Hartogsohn, ) as crucial for the results obtained with these treatments. Set includes circumstances and factors other than drug and pharmacological targets, including people's beliefs, attitudes, preferences, choices and motivations. Setting refers to environment, context, therapists, supporting team etc. Thus, PAP supports other conceptually richer diagnostic approaches considerate of biopsychosocial factors (Frances,; Lefèvre et al.,; Borsboom,; Johnstone, ).

This does not imply that neuroscience is not fundamental to understanding PAP and its consequences for psychiatric research and development. On the contrary. Current limitations of neuroimaging in psychiatry include long-term confounders like smoking, weight and metabolic variations (Linden,; Weinberger and Radulescu, ), and low prognostic accuracy and predictive validity (Linden,; Berkman and Falk,; Weinberger and Radulescu, ). By developing faster treatments and bridging the gap between research and clinical practice, PAP can allow the use of within-subject designs in shorter time spans (e.g., Carhart-Harris et al., ), reducing the impact of confounders and improving reliability of neuroimaging data. Thus, confidence in translating results from acute psychedelic neuroimaging (Vollenweider and Kometer,; Muthukumaraswamy et al.,; Carhart-Harris et al.,,,; Tagliazucchi et al.,; Kraehenmann et al.,; Scheidegger et al.,; Lewis et al.,; Schartner et al., ) to clinical applications which will more closely resemble research designs is increased.

Finally, detailed study of the subjective aspects of PAP has enormous consequences for the explanatory axis. Recent qualitative and phenomenological research shows that psychedelic experiences involve meaningful autobiographical and social psychological concerns (Grof,; MacLean et al.,; Turton et al.,; Baggott et al.,; Gasser et al.,; Schenberg et al.,,; Belser et al.,; Liechti et al.,; Nour and Carhart-Harris,; Watts et al., ). Therefore, PAP can deepen understanding of which psychological contents of the therapeutic experience are most relevant for treatment outcomes (Nour et al.,; Preller and Vollenweider,; Schenberg et al.,,; Carhart-Harris et al., ). This can not only foster improvements in PAP but corroborates the importance of biopsychosocial aspects in psychiatric explanations. A rich methodological integration can help develop theoretical constructs that are not excessively reductionistic. Thus, PAP can conceptually enrich psychiatric explanations for mental disorders and their treatment. If neglect, trauma, childhood adversities, poverty, abuse, and deprivation—i.e., mental injuries—can have lasting negative consequences for mental health, it is also logically plausible that positive, cathartic experiences, sometimes of the mystical type, reliably achieved in PAP, can induce long lasting positive mental health outcomes. Indeed, in the 1950's and 60's, before drug scheduling and cessation of clinical studies with psychedelics, and before neuroscience took central stage in psychiatric understanding of mental disorders, pioneer psychiatrists like Stanislav Grof and Sidney Cohen already questioned the fundamental theoretical grounds of mental disorders (Grof,,,; Cohen, ). Based on theirs' and others' experiences in non-ordinary states of consciousness with positive therapeutic outcomes (termed “holotropic” and “unsane,” respectively), they made radical theoretical proposals that can still be relevant to psychiatry, as it was for psychology (Grob and Bossis, ). It is thus possible that instead of brain dysfunctions causing discrete disorders treated with specific drugs, psychiatry can conceptualize mental injuries causing suffering that can be optimally treated with holistic approaches (Figure 1), including those which modulate the state of consciousness. This can greatly contribute to the understanding of how social circumstances and adverse life experiences shape mental health and brain activity, and how meaningful treatment experiences foster resilience.

Author contributions

The author confirms being the sole contributor of this work and approved it for publication.

Conflict of interest statement

As founder of a startup company the author has a potential conflict of interest due to his involvement with the design of clinical trials with psychedelics in Brazil. He has not been directly involved with any of the previous clinical trials cited in the article.

References 163

  1. 1.

    Abraham H. Aldridge A. M. Gogia P. (1996 ). The psychopharmacology of hallucinogens. Neuropsychopharmacology 14, 285–298.

    Not in our library10.1016/0893-133x(95)00136-2

  2. 2.

    Adam D. (2013 ). Mental health: on the spectrum. Nature 496, 416–418.

    Not in our library10.1038/496416a

  3. 3.

    Alper K. R. (2001 ). Ibogaine: a review. Alkaloids Chem. Biol. 56, 1–38.

    Not in our library10.1016/s0099-9598(01)56005-8

  4. 4.

    Alper K. R. Stajić M. Gill J. R. (2012 ). Fatalities temporally associated with the ingestion of ibogaine. J. Forensic Sci. 57, 398–412.

    Not in our library10.1111/j.1556-4029.2011.02008.x

  5. 5.

    Amoroso T. (2016 ). Ecstasy research: will increasing observational data aid our understanding of MDMA? Lancet Psychiatry 3, 1101–1102.

    Not in our library10.1016/s2215-0366(16)30345-5

  6. 6.

    Amoroso T. Workman M. (2016 ). Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: a preliminary meta-analysis and comparison to prolonged exposure therapy. J. Psychopharmacol. 30, 595–600.

    Not in our library10.1177/0269881116642542

  7. 7.

    Baggott M. J. Kirkpatrick M. G. Bedi G. de Wit H. (2015 ). Intimate insight: MDMA changes how people talk about significant others. J. Psychopharmacol. 29, 669–677.

    Not in our library10.1177/0269881115581962

  8. 8.

    Ballard E. D. Ionescu D. F. Vande Voort J. L. Niciu M. J. Richards E. M. Luckenbaugh D. A.. (2014 ). Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J. Psychiatr. Res. 58, 161–166.

    Not in our library10.1016/j.jpsychires.2014.07.027

  9. 9.
    Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions · 2017
    Not checked
  10. 10.

    Belser A. B. Agin-Liebes G. Swift T. C. Terrana S. Devenot N. Friedman H. L. (2017 ). Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis. J. Humanist Psychol. 57, 354–388.

    Not in our library10.1177/0022167817706884

  11. 11.

    Berkman E. T. Falk E. B. (2013 ). Beyond brain mapping: using neural measures to predict real-world outcomes. Curr. Dir. Psychol. Sci. 22, 45–50.

    Not in our library10.1177/0963721412469394

  12. 12.

    Bloch M. W. Wasylink S. Landeros-Weisenberger A. Panza K. E. Billingslea E. Leckman J. F.. (2012 ). Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol. Psychiatry 72, 964–970.

    Not in our library10.1016/j.biopsych.2012.05.028

  13. 13.

    Bogenschutz M. P. Forcehimes A. A. Pommy J. A. Wilcox C. E. Barbosa P. C. R. Strassman R. (2015 ). Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J. Psychopharmacol. 29, 289–299.

    Not in our library10.1177/0269881114565144

  14. 14.

    Bonny H. L. Pahnke W. N. (1972 ). The use of music in psychedelic (LSD) psychotherapy. J. Music Ther. 9, 64–87.

    Not in our library10.1093/jmt/9.2.64

  15. 15.

    Borsboom D. (2017 ). A network theory of mental disorders. World Psychiatry 16, 5–13.

    Not in our library10.1002/wps.20375

  16. 16.

    Bouso J. C. Doblin R. Farré M. Alcázar M. A. Gómez-Jarabo G. (2008 ). MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. J. Psychoactive Drugs 40, 225–236.

    Not in our library10.1080/02791072.2008.10400637

  17. 17.

    Brown T. K. (2013 ). Ibogaine in the treatment of substance dependence. Curr. Drug Abuse Rev. 6, 3–16.

    Not in our library10.2174/15672050113109990001

  18. 18.

    Brown T. K. Alper K. (2017 ). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am. J. Drug Alcohol Abuse 44, 24–36.

    Not in our library10.1080/00952990.2017.1320802

  19. 19.
    Psilocybin with psychological support for treatment-resistant depression: six-month follow-up · 2017
    No notice
  20. 20.

    Carhart-Harris R. L. Bolstridge M. Rucker J. Day C. M. Erritzoe D. Kaelen M.. (2016 ). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3, 619–627.

    Not in our library10.1016/s2215-0366(16)30065-7

  21. 21.

    Carhart-Harris R. L. Erritzoe D. Haijen E. Kaelen M. Watts R. (2017a ). Psychedelics and connectedness. Psychopharmacology 235, 547–550.

    Not in our library10.1007/s00213-017-4701-y

  22. 22.
    The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs · 2014
    No notice
  23. 23.
    Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms · 2017
    No notice
  24. 24.

    Carhart-Harris R. L. Wall M. B. Erritzoe D. Kaelen M. Ferguson B. De Meer I.. (2014b ). The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. Int. J. Neuropsychopharmacol. 17, 527–540.

    Not in our library10.1017/s1461145713001405

  25. 25.

    Casey B. J. Craddock N. Cuthbert B. N. Hyman S. E. Lee F. S. Ressler K. J. (2013 ). DSM-5 and RDoC: progress in psychiatry research? Nat. Rev. Neurosci. 14, 810–814.

    Not in our library10.1038/nrn3621

  26. 26.

    Catalá-López F. Gènova-Maleras R. Vieta E. Tabarés-Seisdedos R. Svensson M. Jönsson B.. (2013 ). The increasing burden of mental and neurological disorders. Eur. Neuropsychopharmacol. 23, 1337–1339.

    Not in our library10.1016/j.euroneuro.2013.04.001

  27. 27.

    Chapman S. C. Horne R. (2013 ). Medication nonadherence and psychiatry. Curr. Opin. Psychiatry 26, 446–452.

    Not in our library10.1097/yco.0b013e3283642da4

  28. 28.

    Cohen S. (1972 ). Beyond Within: the Lsd Story. New York, NY: Encore Editions.

    Not in our library

  29. 29.

    Coyle C. M. Laws K. R. (2015 ). The use of ketamine as an antidepressant: a systematic review and meta-analysis. Hum. Psychopharmacol. Clin. Exp. 30, 152–163.

    Not in our library10.1002/hup.2475

  30. 30.

    Dakwar E. Hart C. L. Levin F. R. Nunes E. V. Foltin R. W. (2016 ). Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial. Mol. Psychiatry 22, 76–81.

    Not in our library10.1038/mp.2016.39

  31. 31.

    Dakwar E. Levin F. Foltin R. W. Nunes E. V. Hart C. L. (2014 ). The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers. Biol. Psychiatry 76, 40–46.

    Not in our library10.1016/j.biopsych.2013.08.009

  32. 32.

    Deacon B. J. (2013 ). The biomedical model of mental disorder: a critical analysis of its validity, utility, and effects on psychotherapy research. Clin. Psychol. Rev. 33, 846–861.

    Not in our library10.1016/j.cpr.2012.09.007

  33. 33.

    Dos Santos R. G. Osório F. L. Crippa J. A. S. Riba J. Zuardi A. W. Hallak J. E. C. (2016 ). Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Ther. Adv. Psychopharmacol. 6, 193–213.

    Not in our library10.1177/2045125316638008

  34. 34.

    Downing N. S. Aminawung J. A. Shah N. D. Krumholz H. M. Ross J. S. (2014 ). Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005–2012. JAMA 311, 368–377.

    Not in our library10.1001/jama.2013.282034

  35. 35.

    Downing N. S. Shah N. D. Aminawung J. A. Pease A. M. Zeitoun J.-D. Krumholz H. M.. (2017 ). Postmarket safety events among novel therapeutics approved by the us food and drug administration between 2001 and 2010. JAMA 317, 1854–1863.

    Not in our library10.1001/jama.2017.5150

  36. 36.

    Dyck E. (2005 ). Flashback: psychiatric Experimentation with LSD in historical perspective. Can. J. Psychiatry 50, 381–388.

    Not in our library10.1177/070674370505000703

  37. 37.

    Eisner B. (1997 ). Set, setting, and matrix. J. Psychoactive Drugs 29, 213–216.

    Not in our library10.1080/02791072.1997.10400190

  38. 38.

    Feder A. Parides M. K. Murrough J. W. Perez A. M. Morgan J. E. Saxena S.. (2014 ). Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 71, 681–688.

    Not in our library10.1001/jamapsychiatry.2014.62

  39. 39.

    Fond G. Loundou A. Rabu C. Macgregor A. Lançon C. Brittner M.. (2014 ). Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology 231, 3663–3676.

    Not in our library10.1007/s00213-014-3664-5

  40. 40.

    Frances A. (2014a ). RDoC is necessary, but very oversold. World Psychiatry 13, 47–49.

    Not in our library10.1002/wps.20102

  41. 41.

    Frances A. (2014b ). Resuscitating the biopsychosocial model. Lancet Psychiatry 1, 496–497.

    Not in our library10.1016/s2215-0366(14)00058-3

  42. 42.
    Mental disorders as networks of problems: a review of recent insights · 2016
    No notice
  43. 43.

    Frood A. (2012 ). MDMA keeps severe stress at bay. Nature

    Not in our library10.1038/nature.2012.11864

  44. 44.

    Gable R. S. (2004 ). Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction 99, 686–696.

    Not in our library10.1111/j.1360-0443.2004.00744.x

  45. 45.

    Gálvez V. Li A. Huggins C. Glue P. Martin D. Somogyi A. A.. (2018 ). Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial. J. Psychopharmacol. 32, 397–407.

    Not in our library10.1177/0269881118760660

  46. 46.

    Garcia-Romeu A. Griffiths R. R. Johnson M. W. (2015 ). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr. Drug Abuse Rev. 7, 157–164.

    Not in our library10.2174/1874473708666150107121331

  47. 47.

    Gasser P. Holstein D. Michel Y. Doblin R. Yazar-Klosinski B. Passie T.. (2014 ). Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J. Nerv. Ment. Dis. 202, 513–520.

    Not in our library10.1097/nmd.0000000000000113

  48. 48.

    Gasser P. Kirchner K. Passie T. (2015 ). LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J. Psychopharmacol. 29, 57–68.

    Not in our library10.1177/0269881114555249

  49. 49.
    Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial · 2016
    No notice
  50. 50.

    Griffiths R. R. Johnson M. W. Richards W. A. Richards B. D. McCann U. Jesse R. (2011 ). Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology 218, 649–665.

    Not in our library10.1007/s00213-011-2358-5

  51. 51.

    Grinspoon L. (1981 ). LSD Reconsidered. Science 21, 20–23.

    Not in our library10.1002/j.2326-1951.1981.tb01901.x

  52. 52.

    Grob C. S. Bossis A. (2017 ). Humanistic psychology, psychedelics, and the transpersonal vision. J. Humanist. Psychol. 57, 315–318.

    Not in our library10.1177/0022167817715960

  53. 53.

    Grob C. S. Danforth A. L. Chopra G. S. Hagerty M. McKay C. R. Halberstadt A. L.. (2011 ). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch. Gen. Psychiatry 68, 71–78.

    Not in our library10.1001/archgenpsychiatry.2010.116

  54. 54.

    Grof S. (1971 ). Varieties of transpersonal experiences: observations from LSD psychotherapy. J. Transpers. Psychol. 4, 1–45.

    Not in our library

  55. 55.

    Grof S. (1998 ). Human nature and the nature of reality: conceptual challenges from consciousness research. J. Psychoactive Drugs 30, 343–357.

    Not in our library10.1080/02791072.1998.10399710

  56. 56.

    Grof S. (2008 ). LSD Psychotherapy. Ben Lomond, CA: Multidisciplinary Association for Psychedelic Studies.

    Not in our library

  57. 57.

    Grof S. (2012 ). Revision and re-enchantment of psychology: legacy of a half a century of consciousness research. J. Transpers. Psychol. 44, 137–163.

    Not in our library10.1002/9781118591277.ch5

  58. 58.

    Hartogsohn I. (2016 ). Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J. Psychopharmacol. 30, 1259–1267.

    Not in our library10.1177/0269881116677852

  59. 59.

    Hartogsohn I. (2018 ). The meaning-enhancing properties of psychedelics and their mediator role in psychedelic therapy, spirituality, and creativity. Front. Neurosci. 12:129.

    Not in our library10.3389/fnins.2018.00129

  60. 60.

    Hendricks P. S. Clark C. B. Johnson M. W. Fontaine K. R. Cropsey K. L. (2014 ). Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. J. Psychopharmacol. 28, 62–66.

    Not in our library10.1177/0269881113513851

  61. 61.

    Hendricks P. S. Thorne C. B. Clark C. B. Coombs D. W. Johnson M. W. (2015 ). Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J. Psychopharmacol. 29, 280–288.

    Not in our library10.1177/0269881114565653

  62. 62.

    Hyman S. E. (2013 ). Psychiatric drug development: diagnosing a crisis. Cerebrum 2013:5. Available Online at: http://www.dana.org/Cerebrum/2013/Psychiatric_Drug_Development__Diagnosing_a_Crisis/

    Not in our library

  63. 63.

    Iadarola N. D. Niciu M. J. Richards E. M. Vande Voort J. L. Ballard E. D. Lundin N. B.. (2015 ). Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther. Adv. Chronic Dis. 6, 97–114.

    Not in our library10.1177/2040622315579059

  64. 64.

    Insel T. R. (2014 ). The NIMH Research Domain Criteria (RDoC) project: precision medicine for psychiatry. Am. J. Psychiatry 171, 395–397.

    Not in our library10.1176/appi.ajp.2014.14020138

  65. 65.

    Insel T. R. Cuthbert B. N. (2015 ). Brain disorders? Precisely. Science 348, 499–500.

    Not in our library10.1126/science.aab2358

  66. 66.

    Johansen P.-Ø. Krebs T. S. (2015 ). Psychedelics not linked to mental health problems or suicidal behavior: a population study. J. Psychopharmacol. 29, 270–279.

    Not in our library10.1177/0269881114568039

  67. 67.

    Johnson M. Richards W. Griffiths R. (2008 ). Human hallucinogen research: guidelines for safety. J. Psychopharmacol. 22, 603–620.

    Not in our library10.1177/0269881108093587

  68. 68.

    Johnson M. W. Andrew Sewell R. Griffiths R. R. (2012 ). Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend. 123, 132–140.

    Not in our library10.1016/j.drugalcdep.2011.10.029

  69. 69.

    Johnson M. W. Garcia-Romeu A. Cosimano M. P. Griffiths R. R. (2014 ). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J. Psychopharmacol. 28, 983–992.

    Not in our library10.1177/0269881114548296

  70. 70.

    Johnson M. W. Garcia-Romeu A. Griffiths R. R. (2017b ). Long-term follow-up of psilocybin-facilitated smoking cessation. Am. J. Drug Alcohol Abuse 43, 55–60.

    Not in our library10.3109/00952990.2016.1170135

  71. 71.

    Johnson M. W. Griffiths R. R. (2017 ). Potential therapeutic effects of psilocybin. Neurotherapeutics 14, 734–740.

    Not in our library10.1007/s13311-017-0542-y

  72. 72.

    Johnstone L. (2017 ). Psychological formulation as an alternative to psychiatric diagnosis. J. Humanist. Psychol. 58, 30–46.

    Not in our library10.1177/0022167817722230

  73. 73.

    Kaelen M. Barrett F. S. Roseman L. Lorenz R. Family N. Bolstridge M.. (2015 ). LSD enhances the emotional response to music. Psychopharmacology 232, 3607–3614.

    Not in our library10.1007/s00213-015-4014-y

  74. 74.

    Kishimoto T. Chawla J. M. Hagi K. Zarate C. A. Kane J. M. Bauer M.. (2016 ). Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol. Med. 46, 1459–1472.

    Not in our library10.1017/s0033291716000064

  75. 75.

    Koenig X. Hilber K. (2015 ). The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules 20, 2208–2228.

    Not in our library10.3390/molecules20022208

  76. 76.

    Koenig X. Kovar M. Boehm S. Sandtner W. Hilber K. (2014 ). Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk. Addict. Biol. 19, 237–239.

    Not in our library10.1111/j.1369-1600.2012.00447.x

  77. 77.

    Kraehenmann R. Preller K. H. Scheidegger M. Pokorny T. Bosch O. G. Seifritz E.. (2015 ). Psilocybin-Induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol. Psychiatry 78, 572–581.

    Not in our library10.1016/j.biopsych.2014.04.010

  78. 78.

    Kraemer H. C. (2015 ). Research Domain Criteria (RDoC) and the iDSM/i —two methodological approaches to mental health diagnosis. JAMA Psychiatry 72, 1163–1164.

    Not in our library10.1001/jamapsychiatry.2015.2134

  79. 79.

    Krebs T. S. Johansen P.-Ø. (2012 ). Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J. Psychopharmacol. 26, 994–1002.

    Not in our library10.1177/0269881112439253

  80. 80.
    Psychedelics and Mental Health: A Population Study · 2013
    No notice
  81. 81.

    Krupitsky E. M. Burakov A. M. Dunaevsky I. V. Romanova T. N. Slavina T. Y. Grinenko A. Y. (2007 ). Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J. Psychoactive Drugs 39, 13–19.

    Not in our library10.1080/02791072.2007.10399860

  82. 82.

    Krupitsky E. M. Grinenko A. Y. (1997 ). Ketamine psychedelic therapy (KPT): review of the results of ten years of research. J. Psychoactive Drugs 29, 165–183.

    Not in our library10.1080/02791072.1997.10400185

  83. 83.

    Kukreja S. Kalra G. Shah N. Shrivastava A. (2013 ). Polypharmacy in psychiatry: a review. Mens Sana Monogr. 11, 82–99.

    Not in our library10.4103/0973-1229.104497

  84. 84.

    Kupferschmidt K. (2017 ). All clear for the decisive trial of ecstasy in PTSD patients. Science

    Not in our library10.1126/science.aap7739

  85. 85.

    Lee E. E. Della Selva M. P. Liu A. Himelhoch S. (2015 ). Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis. Gen. Hosp. Psychiatry 37, 178–184.

    Not in our library10.1016/j.genhosppsych.2015.01.003

  86. 86.

    Lefèvre T. Lepresle A. Chariot P. (2014 ). An alternative to current psychiatric classifications: a psychological landscape hypothesis based on an integrative, dynamical and multidimensional approach. Philos. Ethics Humanit. Med. 9:12.

    Not in our library10.1186/1747-5341-9-12

  87. 87.

    Lewis C. R. Preller K. H. Kraehenmann R. Michels L. Staempfli P. Vollenweider F. X. (2017 ). Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. Neuroimage 159, 70–78.

    Not in our library10.1016/j.neuroimage.2017.07.020

  88. 88.
    Alterations of consciousness and mystical-type experiences after acute LSD in humans · 2016
    No notice
  89. 89.

    Linden D. E. (2012 ). The challenges and promise of neuroimaging in psychiatry. Neuron 73, 8–22.

    Not in our library10.1016/j.neuron.2011.12.014

  90. 90.

    Luckenbaugh D. A. Niciu M. J. Ionescu D. F. Nolan N. M. Richards E. M. Brutsche N. E.. (2014 ). Do the dissociative side effects of ketamine mediate its antidepressant effects? J. Affect. Disord. 159, 56–61.

    Not in our library10.1016/j.jad.2014.02.017

  91. 91.

    MAPS (2017 ). Investigator's Brochure, 9 th Edn. MAPS.

    Not in our library

  92. 92.

    MacLean K. A. Johnson M. W. Griffiths R. R. (2011 ). Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J. Psychopharmacol. 25, 1453–1461.

    Not in our library10.1177/0269881111420188

  93. 93.

    Majić T. Schmidt T. T. Gallinat J. (2015 ). Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences? J. Psychopharmacol. 29, 241–253.

    Not in our library10.1177/0269881114568040

  94. 94.

    McGirr A. Berlim M. T. Bond D. J. Fleck M. P. Yatham L. N. Lam R. W. (2015 ). A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol. Med. 45, 693–704.

    Not in our library10.1017/s0033291714001603

  95. 95.

    McHugh R. K. Nielsen S. Weiss R. D. (2015 ). Prescription drug abuse: from epidemiology to public policy. J. Subst. Abuse Treat. 48, 1–7.

    Not in our library10.1016/j.jsat.2014.08.004

  96. 96.

    Medic G. Higashi K. Littlewood K. J. Diez T. Granström O. Kahn R. S. (2013 ). Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatr. Dis. Treat. 9, 119–131.

    Not in our library10.2147/ndt.s39303

  97. 97.

    Miller G. (2010 ). Is pharma running out of brainy ideas? Science 329, 502–504.

    Not in our library10.1126/science.329.5991.502

  98. 98.

    Mion G. (2017 ). History of anaesthesia: the ketamine story - past, present and future. Eur. J. Anaesthesiol. 34, 571–575.

    Not in our library10.1097/eja.0000000000000638

  99. 99.

    Mithoefer M. C. Grob C. S. Brewerton T. D. (2016 ). Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry 3, 481–488.

    Not in our library10.1016/s2215-0366(15)00576-3

  100. 100.

    Mithoefer M. C. Wagner M. T. Mithoefer A. T. Jerome L. Doblin R. (2011 ). The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J. Psychopharmacol. 25, 439–452.

    Not in our library10.1177/0269881110378371

  101. 101.
    Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study · 2012
    No notice
  102. 102.

    Mithoefer M. C. Mithoefer A. T. Feduccia A. A. Jerome L. Wymer J. Holland J.. (2018 ). 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry 5, 486–497.

    Not in our library10.1016/s2215-0366(18)30135-4

  103. 103.

    Mojtabai R. Olfson M. (2010 ). National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch. Gen. Psychiatry 67:26.

    Not in our library10.1001/archgenpsychiatry.2009.175

  104. 104.

    Murrough J. W. Soleimani L. DeWilde K. E. Collins K. A. Lapidus K. A. Iacoviello B. M.. (2015 ). Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol. Med. 45, 3571–3580.

    Not in our library10.1017/s0033291715001506

  105. 105.

    Muthukumaraswamy S. D. Carhart-Harris R. L. Moran R. J. Brookes M. J. Williams T. M. Errtizoe D.. (2013 ). Broadband cortical desynchronization underlies the human psychedelic state. J. Neurosci. 33, 15171–15183.

    Not in our library10.1523/jneurosci.2063-13.2013

  106. 106.

    Nichols D. E. (2016 ). Psychedelics. Pharmacol. Rev. 68, 264–355.

    Not in our library10.1124/pr.115.011478

  107. 107.

    Nichols D. E. Johnson M. W. Nichols C. D. (2017 ). Psychedelics as medicines: an emerging new paradigm. Clin. Pharmacol. Ther. 101, 209–219.

    Not in our library10.1002/cpt.557

  108. 108.

    Noller G. E. Frampton C. M. Yazar-Klosinski B. (2017 ). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am. J. Drug Alcohol Abuse 44, 37–46.

    Not in our library10.1080/00952990.2017.1310218

  109. 109.

    Nour M. M. Carhart-Harris R. L. (2017 ). Psychedelics and the science of self-experience. Br. J. Psychiatry 210, 177–179.

    Not in our library10.1192/bjp.bp.116.194738

  110. 110.
    Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI) · 2016
    No notice
  111. 111.
    Nonmedical use of prescription drugs in the European Union · 2016
    No notice
  112. 112.

    Nutt D. J. King L. A. Nichols D. E. (2013 ). Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat. Rev. Neurosci. 14, 577–585.

    Not in our library10.1038/nrn3530

  113. 113.

    Nutt D. J. King L. A. Phillips L. D. (2010 ). Drug harms in the UK: a multicriteria decision analysis. Lancet 376, 1558–1565.

    Not in our library10.1016/s0140-6736(10)61462-6

  114. 114.

    Oehen P. Traber R. Widmer V. Schnyder U. (2013 ). A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J. Psychopharmacol. 27, 40–52.

    Not in our library10.1177/0269881112464827

  115. 115.

    Pahnke W. N. Kurland A. A. Unger S. Savage C. Grof S. (1970 ). The experimental use of psychedelic (LSD) psychotherapy. JAMA J. Am. Med. Assoc. 212, 1856–1863.

    Not in our library10.1001/jama.1970.03170240060010

  116. 116.

    Parnas J. (2014 ). The RDoC program: psychiatry without psyche? World Psychiatry 13, 46–47.

    Not in our library10.1002/wps.20101

  117. 117.

    Parsaik A. K. Singh B. Khosh-Chashm D. Mascarenhas S. S. (2015 ). Efficacy of ketamine in bipolar depression: systematic review and meta-analysis. J. Psychiatr. Pract. 21, 427–435.

    Not in our library10.1097/pra.0000000000000106

  118. 118.

    Passie T. Halpern J. H. Stichtenoth D. O. Emrich H. M. Hintzen A. (2008 ). The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci. Ther. 14, 295–314.

    Not in our library10.1111/j.1755-5949.2008.00059.x

  119. 119.

    Plakun E. (2012 ). Treatment resistance and psychodynamic psychiatry: concepts psychiatry needs from psychoanalysis. Psychodyn. Psychiatry 40, 183–209.

    Not in our library10.1521/pdps.2012.40.2.183

  120. 120.

    Plakun E. M. (2006 ). A view from riggs—treatment resistance and patient authority: i. a psychodynamic perspective on treatment resistance. J. Am. Acad. Psychoanal. Dyn. Psychiatry 34, 349–366.

    Not in our library10.1521/jaap.2006.34.2.349

  121. 121.

    Preller K. H. Vollenweider F. X. (2016 ). Phenomenology, structure, and dynamic of psychedelic states. Curr. Top. Behav. Neurosci. 36, 221–256.

    Not in our library10.1007/7854_2016_459

  122. 122.

    Price R. B. Iosifescu D. V. Murrough J. W. Chang L. C. Al Jurdi R. K. Iqbal S. Z.. (2014 ). Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress. Anxiety 31, 335–343.

    Not in our library10.1002/da.22253

  123. 123.

    Richards W. A. (2017 ). Psychedelic psychotherapy: insights from 25 years of research. J. Humanist. Psychol. 57, 323–337.

    Not in our library10.1177/0022167816670996

  124. 124.

    Rodriguez C. I. Kegeles L. S. Levinson A. Feng T. Marcus S. M. Vermes D.. (2013 ). randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharm 38, 2475–2483.

    Not in our library10.1038/npp.2013.150

  125. 125.

    Rodriguez C. I. Wheaton M. Zwerling J. Steinman S. A. Sonnenfeld D. Galfalvy H.. (2016 ). Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? An open-label trial. J. Clin. Psychiatry 77, 408–409.

    Not in our library10.4088/jcp.15l10138

  126. 126.

    Romeo B. Choucha W. Fossati P. Rotge J.-Y. (2015 ). Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression. Psychiatry Res. 230, 682–688.

    Not in our library10.1016/j.psychres.2015.10.032

  127. 127.

    Rose N. (2016 ). Neuroscience and the future for mental health? Epidemiol. Psychiatr. Sci. 25, 95–100.

    Not in our library10.1017/s2045796015000621

  128. 128.
    Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression · 2018
    No notice
  129. 129.
    Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial · 2016
    No notice
  130. 130.

    Sahakian B. J. Malloch G. Kennard C. (2010 ). A UK strategy for mental health and wellbeing. Lancet 375, 1854–1855.

    Not in our library10.1016/s0140-6736(10)60817-3

  131. 131.

    Saleemi S. Pennybaker S. J. Wooldridge M. Johnson M. W. (2017 ). Who is “Molly”? MDMA adulterants by product name and the impact of harm-reduction services at raves. J. Psychopharmacol. 31, 1056–1060.

    Not in our library10.1177/0269881117715596

  132. 132.
    Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin · 2017
    No notice
  133. 133.

    Scheidegger M. Henning A. Walter M. Lehmann M. Kraehenmann R. Boeker H.. (2016 ). Ketamine administration reduces amygdalo-hippocampal reactivity to emotional stimulation. Hum. Brain Mapp. 37, 1941–1952.

    Not in our library10.1002/hbm.23148

  134. 134.

    Schenberg E. E. de Castro Comis M. A. Alexandre J. F. M. Chaves B. D. R. Tófoli L. F. Silveria D. X. (2016 ). Treating drug dependence with the aid of ibogaine: a qualitative study. J. Psychedelic Stud. 1, 10–19.

    Not in our library10.1177/0269881114552713

  135. 135.

    Schenberg E. E. de Castro Comis M. A. Alexandre J. F. M. Tófoli L. F. Chaves B. D. R. da Silveira D. X. (2017 ). A phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment. J. Psychedelic Stud. 1, 74–83.

    Not in our library10.1556/2054.01.2017.007

  136. 136.

    Schenberg E. E. de Castro Comis M. A. Chaves B. R. da Silveira D. X. (2014 ). Treating drug dependence with the aid of ibogaine: a retrospective study. J. Psychopharmacol. 28, 993–1000.

    Not in our library10.1556/2054.01.2016.002

  137. 137.

    Short B. Fong J. Galvez V. Shelker W. Loo C. K. (2017 ). Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry 5, 65–78.

    Not in our library10.1016/s2215-0366(17)30272-9

  138. 138.

    Smith D. E. Raswyck G. E. Dickerson Davidson L. (2014 ). From hofmann to the haight ashbury, and into the future: the past and potential of Lysergic Acid Diethlyamide. J. Psychoactive Drugs 46, 3–10.

    Not in our library10.1080/02791072.2014.873684

  139. 139.

    Stephan K. E. Bach D. R. Fletcher P. C. Flint J. Frank M. J. Friston K. J.. (2016a ). Charting the landscape of priority problems in psychiatry, part 1: classification and diagnosis. Lancet Psychiatry 3, 77–83.

    Not in our library10.1016/s2215-0366(15)00361-2

  140. 140.

    Stephan K. E. Binder E. B. Breakspear M. Dayan P. Johnstone E. C. Meyer-Lindenberg A.. (2016b ). Charting the landscape of priority problems in psychiatry, part 2: pathogenesis and aetiology. Lancet Psychiatry 3, 84–90.

    Not in our library10.1016/s2215-0366(15)00360-0

  141. 141.

    Studerus E. Kometer M. Hasler F. Vollenweider F. X. (2011 ). Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J. Psychopharmacol. 25, 1434–1452.

    Not in our library10.1177/0269881110382466

  142. 142.

    Tagliazucchi E. Carhart-Harris R. Leech R. Nutt D. Chialvo D. R. (2014 ). Enhanced repertoire of brain dynamical states during the psychedelic experience. Hum. Brain Mapp. 35, 5442–5456.

    Not in our library10.1002/hbm.22562

  143. 143.

    Togni L. R. Lanaro R. Resende R. R. Costa J. L. (2015 ). The variability of ecstasy tablets composition in Brazil. J. Forensic Sci. 60, 147–151.

    Not in our library10.1111/1556-4029.12584

  144. 144.

    Turton S. Nutt D. J. Carhart-Harris R. L. (2014 ). A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment. Curr. Drug Abuse Rev. 7, 117–127.

    Not in our library10.2174/1874473708666150107120930

  145. 145.

    Tylš F. Páleníček T. Horáček J. (2014 ). Psilocybin–summary of knowledge and new perspectives. Eur. Neuropsychopharmacol. 24, 342–356.

    Not in our library10.1016/j.euroneuro.2013.12.006

  146. 146.

    van Amsterdam J. Opperhuizen A. van den Brink W. (2011 ). Harm potential of magic mushroom use: a review. Regul. Toxicol. Pharmacol. 59, 423–429.

    Not in our library10.1016/j.yrtph.2011.01.006

  147. 147.

    van Gerven J. Cohen A. (2011 ). Vanishing clinical psychopharmacology. Br. J. Clin. Pharmacol. 72, 1–5.

    Not in our library10.1111/j.1365-2125.2011.04021.x

  148. 148.

    Vizeli P. Liechti M. E. (2017 ). Safety pharmacology of acute MDMA administration in healthy subjects. J. Psychopharmacol. 31, 576–588.

    Not in our library10.1177/0269881117691569

  149. 149.

    Vogels N. Brunt T. M. Rigter S. van Dijk P. Vervaeke H. Niesink R. J. M. (2009 ). Content of ecstasy in the Netherlands: 1993–2008. Addiction 104, 2057–2066.

    Not in our library10.1111/j.1360-0443.2009.02707.x

  150. 150.

    Vollenweider F. X. Kometer M. (2010 ). The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat. Rev. Neurosci. 11, 642–651.

    Not in our library10.1038/nrn2884

  151. 151.

    Vrolijk R. Q. Brunt T. M. Vreeker A. Niesink R. J. M. (2017 ). Is online information on ecstasy tablet content safe? Addiction 112, 94–100.

    Not in our library10.1111/add.13559

  152. 152.

    Wacker D. Wang S. McCorvy J. D. Betz R. M. Venkatakrishnan A. J. Levit A.. (2017 ). Crystal structure of an LSD-bound human serotonin receptor. Cell 168, 377–389.

    Not in our library10.1016/j.cell.2016.12.033

  153. 153.

    Wakefield J. C. (2014 ). Wittgenstein's nightmare: why the RDoC grid needs a conceptual dimension. World Psychiatry 13, 38–40.

    Not in our library10.1002/wps.20097

  154. 154.

    Wan L.-B. Levitch C. F. Perez A. M. Brallier J. W. Iosifescu D. V. Chang L. C.. (2015 ). Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J. Clin. Psychiatry 76, 247–252.

    Not in our library10.4088/jcp.13m08852

  155. 155.

    Watts R. Day C. Krzanowski J. Nutt D. Carhart-Harris R. (2017 ). Patients' accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression. J. Humanist. Psychol. 57, 520–564.

    Not in our library10.1177/0022167817709585

  156. 156.

    Weinberger D. R. Radulescu E. (2016 ). Finding the elusive psychiatric “lesion” with 21st-century neuroanatomy: a note of caution. Am. J. Psychiatry 173, 27–33.

    Not in our library10.1176/appi.ajp.2015.15060753

  157. 157.

    Whiteford H. A. Degenhardt L. Rehm J. Baxter A. J. Ferrari A. J. Erskine H. E.. (2013 ). Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010. Lancet 382, 1575–1586.

    Not in our library10.1016/s0140-6736(13)61611-6

  158. 158.

    Wilkinson S. T. Wright D. Fasula M. K. Fenton L. Griepp M. Ostroff R. B.. (2017 ). Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. Psychother. Psychosom. 86, 162–167.

    Not in our library10.1159/000457960

  159. 159.

    Winkelman M. (2014 ). Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca. Curr. Drug Abuse Rev. 7, 101–116.

    Not in our library10.2174/1874473708666150107120011

  160. 160.

    Wood D. M. Stribley V. Dargan P. I. Davies S. Holt D. W. Ramsey J. (2011 ). Variability in the 3,4-methylenedioxymethamphetamine content of “ecstasy” tablets in the UK. Emerg. Med. J. 28, 764–765.

    Not in our library10.1136/emj.2010.092270

  161. 161.

    Wright E. R. Kooreman H. E. Greene M. S. Chambers R. A. Banerjee A. Wilson J. (2014 ). The iatrogenic epidemic of prescription drug abuse: county-level determinants of opioid availability and abuse. Drug Alcohol Depend. 138, 209–215.

    Not in our library10.1016/j.drugalcdep.2014.03.002

  162. 162.
    Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis · 2015
    No notice
  163. 163.

    Yazar-Klosinski B. B. Mithoefer M. C. (2017 ). Potential psychiatric uses for MDMA. Clin. Pharmacol. Ther. 101, 194–196.

    Not in our library10.1002/cpt.565

Cited by papers we hold 3

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.